Search Results for: car t

Duke letter to White House on the problems with the TPP IP Chapter

Posted on by KEI Staff

Attached below is a May 20, 2015 letter from Duke researchers to the White House Office of Science and Technology Policy, setting our problems in the TPP IP Chapter. The letter is signed by Jason Cross, the Director of the Innovation & Technology Policy Lab (ITPLab) at the Sanford School of Public Policy & Duke Law School, at Duke University.

The whole letter (available in PDF format here) is worth reading. Here are a few sections from the letter:

Continue Reading →

Uncategorized

Two page summary: What does the TPP do as regards prices of drugs and other medical technologies?

Posted on by Claire Cassedy

Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.

A pdf version of the note is available here: /wp-content/uploads/KEI-TPP-Briefing-2015-2-A2M.pdf

What does the TPP do as regards prices of drugs and other medical technologies?

KEI TPP Briefing note 2015:2
June 10, 2015
Continue Reading →

WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical products

Posted on by Thiru

Today, on Wednesday, 10 June 2015, the World Trade Organization’s TRIPS Council discussed the LDC Group’s Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605). Continue Reading →

Uncategorized

June 2015: WTO reports on India’s Section 3(d) and compulsory licensing provisions – WTO Trade Policy Review – India

Posted on by Thiru

On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures” (Source: WTO, Trade Policy Reviews: Brief Introduction).

Continue Reading →

Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.

Posted on by KEI Staff

Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary “to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease.”

Continue Reading →

UACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDs

Posted on by Manon Ress

To prepare for the upcoming 68th World Health Assembly (WHA), the U.S. Department of Health & Human Services held a Stakeholder Listening Session on Friday, May 8, 2015, from 10:30am – 12pm in the HHS Humphrey Building – 200 Independence Ave, SW, Washington, DC 20201. All Agenda items for the upcoming WHA are here:
http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
Continue Reading →

Uncategorized

KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data

Posted on by KEI Staff

Rajasingh-1-IMG_3157_1024x716.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:

Continue Reading →